Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 19/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629928 | 0.93 | NR3C1 (0.54) | NR3C1PGR | |
| SCHEMBL4630426 | 0.81 | NR3C1 (0.42) | NR3C1PGR | |
| SCHEMBL4628521 | 0.79 | NR3C1 (0.39) | NR3C1PGR | |
| SCHEMBL14086563 | 0.78 | NR3C1 (0.53) | NR3C1PGR | |
| SCHEMBL4629080 | 0.77 | NR3C1 (0.61) | NR3C1PGR | |
| SCHEMBL4735534 | 0.77 | NR3C1 (0.47) | NR3C1PGR | |
| SCHEMBL4628801 | 0.76 | NR3C1 (0.44) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4627623 | 0.76 | NR3C1 (0.48) | NR3C1CCR1PGR | |
| SCHEMBL4629065 | 0.76 | NR3C1 (0.48) | NR3C1PGR | |
| SCHEMBL6408234 | 0.75 | NR3C1 (0.38) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188666-A1 | LINEAR PHENYL-SUBSTITUTED INDAZOLES AND INDOLES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| EP-1921067-A1 | Indole and indazole derivatives as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188666-A1 | LINEAR PHENYL-SUBSTITUTED INDAZOLES AND INDOLES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | IDO1, IL1B, IDO2 | NR3C1 1243/4885CCR1 755/4885PGR 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.